SLC5A2 and diabetes mellitus: For HF, SGLT2 inhibitors have become a standard guideline-directed medical therapy across the entire spectrum of the left ventricular ejection fraction, regardless of diabetes status, according to recent landscape-event-driven trials (EMPEROR-Preserved, EMPEROR-Reduced, DELIVER, DAPA-HF) [3,4,5,6,7,8,9,10].